CN101239216A - Novel sacculus dilating catheter - Google Patents
Novel sacculus dilating catheter Download PDFInfo
- Publication number
- CN101239216A CN101239216A CNA2008100185229A CN200810018522A CN101239216A CN 101239216 A CN101239216 A CN 101239216A CN A2008100185229 A CNA2008100185229 A CN A2008100185229A CN 200810018522 A CN200810018522 A CN 200810018522A CN 101239216 A CN101239216 A CN 101239216A
- Authority
- CN
- China
- Prior art keywords
- sacculus
- dilating catheter
- wingfold
- novel
- drug material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.
Description
Technical field
The present invention relates to a kind of sacculus dilating catheter, the novel sacculus dilating catheter of the integral structure design of the administration that is specifically related to fix a point.This novel sacculus dilating catheter is particularly suitable for treating coronary artery, carotid artery and other angiopathys.
Background technology
Along with growth in the living standard, patients with coronary heart disease is increasing, and cardiovascular narrow be the one of the main reasons that causes coronary heart disease.The method that initial doctor adopts cardiovascular to put up a bridge solves this class problem, but along with development of science and technology, (Percutaneous Coronary Intervention PCI) becomes the main means for the treatment of this class patient to interventional therapy.Beginning, the doctor adopts sacculus dilating catheter to enter patient's diseased region via seal wire, adopts the full method of high pressure with balloon expandable, enlarges narrow lesion vessels.But very fast discovery, after such operation patient's blood vessel very fast occur again narrow.So new interventional therapeutic technique becomes one of coronary heart disease conventional treatments, it is the support that pressure is held a metal structure on sacculus dilating catheter, after entering diseased region, adopt that high pressure is full also to come the support expansion with balloon expandable the time and supporting lesion vessels, this Therapeutic Method success rate can reach more than 95%.But the operation back had 25～50% patient that vascular restenosis can take place in 3-6 month, had therefore limited the late result of PCI.
Research thinks that the mechanism that vascular restenosis takes place behind the stenting is: human vas causes the endotheliocyte and the smooth muscle cell damage of blood vessel wall after support or the expansion of other implantation instruments, can cause thrombosis and inflammatory reaction.Follow the release of hematoblastic cell growth factor, the propagation of stimulated vascular smooth muscle cell and migration.The smooth muscle cell that is activated is synthetic phenotype by shrinking phenotypic transformation, and in impaired back 3 days, about 40% middle film smooth muscle cell enters cell generation cycle.New synthetic cell migration is secreted a large amount of extracellular matrixs to the smooth muscle theca interna.Simultaneously, inflammatory cell can be attacked damage location, the more deep layer of intravasation wall.The endotheliocyte of dysfunction is also contributed to some extent to the propagation and the migration of smooth muscle cell.Endothelium up to damaged part grows up to again, and intimal proliferation just slows down gradually, yet extracellular matrix increases and further causes intimal thickening.This multiple bioprocess acts on the generation of the restenosis that has caused the postoperative blood vessel simultaneously.
At present, abroad the expert has carried out more deep research for the inaccessible again main cause that forms of reconstructing blood vessel postoperative, finds that Fibrinogen (Fibrinogen), atheroma formation (Atherogenesis), condense (Coagulation/Hemostasis), hematodinamics (Rheology/Vasotonus), vascular inflammation (Vascular/Inflammation) are the principal elements of restenosis behind the formation reconstructing blood vessel.And above any one mechanism all can cause the activation of other mechanism, and mutually promotes, enlarge mutually, and vascular endothelial cell injury, and further increase the weight of to enlarge effect, form vicious cycle; Simultaneously, the expansion effect of four mechanism can suppress propagation, the differentiation of endothelial progenitor cell (EPC), the EPC function is reduced, and vascular endothelial cell can not normally be repaired.Finally cause vascular endothelial injury to increase the weight of, atherosclerotic plaque constantly thickens and breaks, thrombosis, intimal thickening (compensatory repairing), therefore, the EPC functional defect is the important pathogenesis of atherosclerosis thrombosis and cardiovascular diseases and postoperative restenosis.
Along with the extensive use of medicine slow release stent system and the continuous development of new technique, people are more deep to the medicine slow release stent systematic research.In operation, find, in the support implantable intravascular,, inevitably blood vessel is rubbed, thereby caused damage because the expansion of the support of metal structure is supported.After surgery, needs of patients is taken anticoagulation medicine to avoid the formation of thrombosis.With respect to the bare bracket that does not have medication coat, vascular endothelial cell can heal automatically in 30 days, and the patient needn't take anticoagulation medicine again, but the probability that restenosis takes place is 25～50%.And medicine (comprising rapamycin and derivant thereof, paclitaxel and derivant thereof) has postponed the healing of vascular endothelial cell though slow release stent has effectively suppressed the hypertrophy of vascular cell owing to the slow release of medicine.Caused support to implant the lethal potential danger of acute thrombus has taken place late period.Show that according to relevant data medicine slow release stent still has the case that acute thrombus takes place to occur at implantable intravascular after 2 years.So the implantation rate of west some national drug slow release stent systems (DES) drops to present 70% from 90% of the first two years.
Summary of the invention
The object of the invention provides a kind of novel sacculus dilating catheter, can treat the medicine of vascular lesion by coating on sacculus dilating catheter, alternative slow releasing pharmaceutical supports such as thunderous handkerchief mycin, the interventional therapy that solves the slow releasing pharmaceutical support is implanted the easy lethal problem of acute thrombus that takes place in late period at support.
For achieving the above object, the technical solution used in the present invention is: a kind of novel sacculus dilating catheter, comprise sacculus and the drug material that is coated on the sacculus, described drug material is selected heparin sodium, Defibrase, serine protease, batroxobin, aspirin, trihydroxy-isoflavone, hirudin and reorganization product thereof, colchicine, Sirolimus, Everolimus, Biolimus, Zotarolimus, Tracrolimus, Pimecrolimus, simvastatin, lovastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, rubidomycin, ametycin, actinomycin D, paclitaxel, tripterine, methotrexate, 5-fluorouracil, a kind of or two kinds and two or more mixture in cytosine arabinoside and the Ismipur.
In the such scheme, described sacculus is three wingfold sacculus or four wingfold sacculus.
Because the technique scheme utilization, the present invention compared with prior art has following advantage and effect:
1, sacculus of the present invention is to be made by the macromolecule nylon material, the stimulation that in process of expansion blood vessel is caused stimulates the damage that blood vessel causes well below the support of metal structure, and in the balloon expandable process, the medicine that applies on the sacculus can contact with the vascular lesion position fully, absorbed by vascular endothelial cell, realize the fixed point administration, thereby reach the effect of treatment.
2, the present invention realizes that the fixed point of medicine discharges, and can simplify doctor's operation process.
3, the present invention has saved metal rack, can save a large sum of medical expense for the patient.Do not have metallic foreign body to be detained in vivo after the treatment, avoided the generation of all kinds of sequela that cause thus.
Description of drawings
Accompanying drawing 1 is three wingfold medication coat sacculus;
Accompanying drawing 2 is four wingfold medication coat sacculus;
Accompanying drawing 3 is the sacculus dilating catheter sketch map.
In the above accompanying drawing: 1, sacculus silk-guiding chamber; 2, medication coat; 3 sacculus folding wings; 6, sacculus.
The specific embodiment
Below in conjunction with drawings and Examples the present invention is further described:
Embodiment one: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 1 and 3, novel sacculus dilating catheter comprises three wingfold sacculus and the drug material that is coated on the three wingfold sacculus, drug material is selected heparin sodium, utilize carrier material such as polyethylene etc. then, heparin sodium is coated on the surface of three wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material to obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
Embodiment two: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 1 and 3, novel sacculus dilating catheter comprises three wingfold sacculus and the drug material that is coated on the three wingfold sacculus, drug material is selected Defibrase and serine stretch protein enzymatic mixture, utilize the mixture of carrier material polypropylene and polylactic acid then, drug material is coated on the surface of three wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material to obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
Embodiment three: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 1 and 3, novel sacculus dilating catheter comprises three wingfold sacculus and the drug material that is coated on the three wingfold sacculus, drug material is selected Sirolimus, batroxobin mixture and lovastatin, utilize the carrier material isopropyl lactate then, drug material is coated on the surface of three wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material to obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
Embodiment four: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 1 and 3, novel sacculus dilating catheter comprises three wingfold sacculus and the drug material that is coated on the three wingfold sacculus, drug material is selected plicamycin, 5-fluorouracil, batroxobin, with the Biolimus mixture, utilize the carrier material propyl lactate then, butyl lactate, lactic acid monooctyl ester and lactose mixture, drug material is coated on the surface of three wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
Embodiment five: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 2 and 3, novel sacculus dilating catheter comprises four wingfold sacculus and the drug material that is coated on the four wingfold sacculus, drug material is selected trihydroxy-isoflavone and Zotarolimus, utilize the mixture of carrier material polypropylene and polylactic acid then, drug material is coated on the surface of four wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material to obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
Embodiment six: a kind of novel sacculus dilating catheter
Shown in accompanying drawing 2 and 3, novel sacculus dilating catheter comprises four wingfold sacculus and the drug material that is coated on the four wingfold sacculus, drug material is selected paclitaxel, cytosine arabinoside and aspirin mixture, utilize the carrier material methyl lactate then, drug material is coated on the surface of four wingfold sacculus, the mode of bag quilt can adopt spraying, soaking method or sacculus matrix material to obtain medication coat by process for treating surface, and these process for treating surface comprise heat treatment, bead, electrochemical treatments and supersound process etc.
The foregoing description only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the personage who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalences that spirit is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (2)
1, a kind of novel sacculus dilating catheter, comprise sacculus and the drug material that is coated on the sacculus, it is characterized in that: described drug material is selected heparin sodium, Defibrase, serine protease, batroxobin, aspirin, trihydroxy-isoflavone, hirudin and reorganization product thereof, colchicine, Sirolimus, Everolimus, Biolimus, Zotarolimus, Tracrolimus, Pimecrolimus, simvastatin, lovastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, rubidomycin, ametycin, actinomycin D, paclitaxel, tripterine, methotrexate, 5-fluorouracil, a kind of or two kinds and two or more mixture in cytosine arabinoside and the Ismipur.
2, novel sacculus dilating catheter according to claim 1 is characterized in that: described sacculus is three wingfold sacculus or four wingfold sacculus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100185229A CN101239216A (en) | 2008-02-20 | 2008-02-20 | Novel sacculus dilating catheter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100185229A CN101239216A (en) | 2008-02-20 | 2008-02-20 | Novel sacculus dilating catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101239216A true CN101239216A (en) | 2008-08-13 |
Family
ID=39931214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100185229A Pending CN101239216A (en) | 2008-02-20 | 2008-02-20 | Novel sacculus dilating catheter |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239216A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149328A1 (en) * | 2011-04-29 | 2012-11-01 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
| CN103750884A (en) * | 2013-12-25 | 2014-04-30 | 上海长征医院 | Uterine cavity expansion tri-Lobe balloon catheter |
| CN104027849A (en) * | 2014-06-30 | 2014-09-10 | 四川大学 | Soy isoflavone supported biological composite material porous scaffold and preparation |
| CN104056341A (en) * | 2014-06-24 | 2014-09-24 | 深圳市金瑞凯利生物科技有限公司 | Medicament balloon and preparation method thereof |
| CN105288823A (en) * | 2015-11-27 | 2016-02-03 | 王显 | Drug eluting balloon system |
| CN114748701A (en) * | 2022-03-22 | 2022-07-15 | 乐普（北京）医疗器械股份有限公司 | Drug coating, drug balloon, preparation method and application of drug balloon |
-
2008
- 2008-02-20 CN CNA2008100185229A patent/CN101239216A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149328A1 (en) * | 2011-04-29 | 2012-11-01 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
| US20120277843A1 (en) * | 2011-04-29 | 2012-11-01 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
| US9061127B2 (en) | 2011-04-29 | 2015-06-23 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
| CN103750884A (en) * | 2013-12-25 | 2014-04-30 | 上海长征医院 | Uterine cavity expansion tri-Lobe balloon catheter |
| CN104056341A (en) * | 2014-06-24 | 2014-09-24 | 深圳市金瑞凯利生物科技有限公司 | Medicament balloon and preparation method thereof |
| CN104056341B (en) * | 2014-06-24 | 2017-01-18 | 深圳市金瑞凯利生物科技有限公司 | Medicament balloon preparation method |
| CN104027849A (en) * | 2014-06-30 | 2014-09-10 | 四川大学 | Soy isoflavone supported biological composite material porous scaffold and preparation |
| CN104027849B (en) * | 2014-06-30 | 2016-02-10 | 四川大学 | Carry Biocomposite material porous support and the preparation of soybean isoflavone |
| CN105288823A (en) * | 2015-11-27 | 2016-02-03 | 王显 | Drug eluting balloon system |
| CN114748701A (en) * | 2022-03-22 | 2022-07-15 | 乐普（北京）医疗器械股份有限公司 | Drug coating, drug balloon, preparation method and application of drug balloon |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2360646C2 (en) | Endoluminal prosthesis containing medical agent | |
| CN104013996B (en) | The drug eluting implantable medical device of progenitor endothelial cell capturing | |
| ES2383374T3 (en) | PEC Polymer Coated Devices | |
| EP2219554A1 (en) | Progesterone-containing compositions and devices | |
| KR20080073328A (en) | Controlled drug release composition and drug releasing medical device | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| CN103948975B (en) | A kind of targeted drug release gets involved class medical apparatus and instruments and preparation method thereof | |
| EP3030274B1 (en) | Method of treating peripheral artery diseases in lower limbs | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| JP2004173770A (en) | In vivo implanting medical appliance | |
| JP2008529667A (en) | Medical device | |
| JP4588986B2 (en) | Implantable medical device | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| US20060286141A1 (en) | Systems for gel-based medical implants | |
| US20080085293A1 (en) | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor | |
| JP2004222953A (en) | Indwelling stent | |
| JP2008253707A (en) | Drug-eluting stent | |
| EP3520789B1 (en) | New use of amlexanox | |
| JP7033694B2 (en) | Drug-eluting stent | |
| US20080311086A1 (en) | Use of Keratinocyte Composition for the Treatment of Restenosis | |
| CN208243663U (en) | A kind of Nano medication delayed release device as intravascular stent outsourcing | |
| JP2010155095A (en) | Medical instrument to be implanted in the body | |
| CN112263360A (en) | In vivo drug eluting stent and preparation method thereof | |
| TW201620551A (en) | Stent of drug-dissolution type | |
| CN114126678A (en) | Stent with immediately removable coating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080813 |